Abeona Therapeutics ABEOW 深 沪
已收盘 01-09 16:00:00 美东时间
0.0698
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0698
- 总市值 2.11亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.021
- 委 比 0.00%
- 总股本 30.28亿
- 历史最高 17.56
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.021
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to 11 new non-executive employees, totaling up to 71,035 shares. The shares vest annually over three years, contingent on continued employment. The company specializes in cell and gene therapies, with ZEVASKYN being its flagship product for treating wounds in patients with recessive dystrophic epidermolysis bullosa.
11-03 12:30
Abeona Secures Permanent CMS J-Code J3389 For ZEVASKYN Gene Therapy In Recessive Dystrophic Epidermolysis Bullosa; New J-Code Becomes Effective January 1, 2026
Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has
10-30 22:48
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
Abeona Therapeutics announced that CMS has established a permanent HCPCS J-code (J3389) for ZEVASKYN, a gene therapy for treating wounds in RDEB patients. The code will take effect on January 1, 2026, simplifying claims processing and improving patient access. ZEVASKYN uses the patient's own skin cells to produce functional collagen, addressing a severe genetic skin disorder.
10-30 14:45
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
10-13 19:18
Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent
Krystal Biotech (NASDAQ:KRYS) announced Thursday a revamped product pipeline after a decision to prioritize studies for an inhaled version of its antitumor candidate KB707 targeted at non-small cell l...
08-22 00:59
Oppenheimer Maintains Outperform on Abeona Therapeutics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and raises the price target from $19 to $20.
08-15 22:35
快讯 | Abeona Therapeutics, Inc.：Oppenheimer 将目标价从 19 美元上调至 20 美元
Abeona Therapeutics, Inc. : Oppenheimer Raises Target Price to $20 From $19
08-15 20:12
Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Abeona Therapeutics shares are trading higher after the company reported better...
08-14 22:14
Abeona Therapeutics Q2 EPS $1.71 Beats $(0.39) Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly earnings of $1.71 per share which beat the analyst consensus estimate of $(0.39) by 543.01 percent. This is a 757.69 percent increase over losses of $(0.26) per share
08-14 19:40
AscellaHealth Partnership With Abeona Therapeutics Highlights The Launch Commercialization Of ZEVASKYN, An FDA-Approved Cell-Based Gene Therapy
BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partnership with Abeona
07-29 22:04
